IKF Pneumologie GmbH & Co. KG — Clinical Trial Site

63 Registered trials

27 Currently recruiting

Organisation

IKF Pneumologie GmbH & Co. KG

Location

Frankfurt Am Main, Germany

Identifier

ORG-100046278

Address

Stresemannallee 3, Sachsenhausen, 60596, Germany

Departments

-
#2604
2602: Pulmonology
2604: Helix Medical Excellence Center Mainz
2605:Institut für klinische Forschung Pneumologie
2606: Institut für klinische Forschung
276001:Pulmonology
276003:Institut für klinische Forschung Pneumologie
2nd Floor
4501: Institut für klinische Forschung Pneumologie
4518: Pulmonology
Clinical Research Center Respiratory Diseases
Clinical Research Centre Respiratory Diseases
Clinical Research Centre, Respiratory Medicine, Helix Medical Excellence Center
DE007: Pulmonology
Helix Medical Excellence Center Mainz
IKF Institut für Klinische Forschung Mainz
IKF Pneumologie GmbH & Co. KG
IKF Pneumologie GmbH & Co. KG (#1)
IKF Pneumologie Mainz
Institut für klinische Forschung Pneumologie
Institut für Klinische Forschung Pneumologie Frankfurt
Institut für klinische Forschung Pneumologie, Clinical Research Center Respiratory Diseases
Interdisziplinaeres Facharztentrum Sachsenhausen
Interdisziplinäres Facharztzentrum
Interdisziplinäres Facharztzentrum Sachsenhausen
lnstitut fuer klinische Forschung Pneumologie
N/A
N/A - Additional streetname as site is located at a corner: Stresemannallee 3
NA
Not applicable
Pneumologie
Pneumology
Pulmonology, Endocrinology, Cardiovascular Diseases

Clinical trials at this site (63)

Search interface

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma Ended

2024-519469-23-00 Severe Asthma 4 2025-10-20
Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended

2025-520488-42-00 Moderate-to-Severe Chronic Obstructive Pulmonary Diseas 4 2025-09-17
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease Ended

2023-506880-32-01 Pulmonary Disease, Chronic Obstructive 1 2025-04-14
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation t… Ended

2023-510458-18-00 Asthma 6 2025-03-11
A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended

2024-514228-18-00 Asthma in adults who remain uncontrolled despite medium 4 2025-01-16
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex… Ended

2024-513462-19-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-30
A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharma… Ended

2024-516474-30-00 Asthma 3 2025-02-19
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adu… Ended

2024-514213-35-00 Asthma 3 2025-01-20
Open-Label Extension of EryDex in A-T (OLE NEAT) Ended

2024-513618-37-00 Ataxia Telangiectasia (A-T) 5 2024-12-23
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Influenza 5 2024-10-11
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos… Ended

2023-506000-50-00 Adult Patients with Moderate-to-Severe Asthma Uncontrol 4 2024-09-26
A trial to learn how AZD4604 acts in the body and how safe it is in adults with asthma Ended

2023-510291-32-00 Asthma 4 2024-09-26
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr… Ended

2023-506185-31-00 Idiopathic pulmonary fibrosis (IPF) 10 2024-07-18
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended

2023-507410-27-00 Severe Asthma 4 2024-06-19
A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Bronchiectasis 4 2024-06-18
A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis Ended

2023-504092-25-00 Cystic Fibrosis 4 2024-06-04
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te… Ended

2023-509077-23-00 Ataxia Telangiectasia 5 2024-06-03
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended

2023-503693-20-01 Severe eosinophilic asthma 5 2024-04-10
A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma Ended

2023-504304-29-00 Moderate to Severe Asthma 3 2024-03-01